Is it time to revisit the role of psychedelic drugs in enhancing human creativity?

Sessa frames the paper within the contemporary 'renaissance' of clinical research into psychedelic drugs and notes that most modern work has concentrated on therapeutic applications. He argues that, alongside these clinical avenues, psychedelics deserve renewed attention for what they might reveal about cognition more broadly, and in particular their potential role in enhancing creativity. The introduction sets out the basic problem for such a programme of research: creativity is difficult to define and measure, so any effort to test whether psychedelic drugs enhance creative thinking must begin with careful consideration of what is meant by creativity and how it can be assessed. Sessa therefore motivates a review of historical studies, anecdotal reports and relevant neuroscientific ideas to establish whether revisiting this area with contemporary methods is warranted.

The extracted text does not describe a formal methods section typical of a systematic review. Instead, Sessa presents a narrative review and historical overview that draws on anecdotal reports, early empirical studies from the 1950s–1960s, selected experimental papers, and recent replications (for example the Johns Hopkins psilocybin work). There is no clear reporting of search strategy, databases consulted, inclusion or exclusion criteria, or a risk-of-bias assessment in the extracted text. Accordingly, the paper synthesises conceptual material (definitions and models of creativity), neuroscientific ideas, historical anecdotes of artists and scientists, and a selective summary of small experimental studies that examined the acute and longer-term effects of psychedelic drugs on measures of creativity or related behaviours. Where numerical or methodological details are available from those original studies, Sessa summarises them, but readers should note this is a narrative account rather than a systematic meta-analysis.

Sessa organises the evidence into conceptual, neuroscientific, historical and empirical strands. On definition and measurement, creativity is presented as generation of novel ideas or associations. The paper reviews classical models such as Wallas's stages of the creative process and the distinction between convergent and divergent thinking. Psychometric approaches to measuring creativity are discussed, including divergent-thinking tests (examples: Unusual Uses test, Mednick's Remote Associates) and the Torrance Tests of Creative Thinking (TTCT). Expert judgement methods such as Amabile's Consensual Assessment Technique are noted as an alternative when objective scoring is difficult. From a neurobiological perspective, Sessa summarises proposals that creativity arises from interactions among temporal and frontal cortical regions and limbic structures, with neurotransmitter systems such as dopamine and norepinephrine implicated. He cites models proposing co-activation of normally weakly connected brain regions and the role of divergent thinking mediated by frontal systems. Historical and anecdotal material is substantial. Sessa recounts many artists and scientists who have reported psychedelic-influenced creativity, from pre‑historic art to 20th‑century figures such as Aldous Huxley, Henri Michaux, and anecdotal claims about figures in science and technology (examples include quoted recollections by Kary Mullis and suggested LSD use by Francis Crick). Oscar Janiger's long-term, largely naturalistic programme is summarised: between 1954 and 1962 he facilitated almost 1,000 LSD sessions and later ran a controlled series with about 60 visual artists producing over 250 drawings; qualitative reports from participants were uniformly positive though objective inferences were limited by heterogeneity and aesthetic judgement. Sessa summarises several small experimental studies from the mid‑20th century with mixed findings. Examples include a study giving 200 µg LSD to 72 graduate students with two control groups that led to greater long‑term subjective appreciation of arts but no measured increase in creativity, and an experiment with 19 students receiving varying LSD doses and 11 receiving placebo that failed to show statistically significant improvements but indicated trends and suggested that certain subjects with 'creative' personality traits showed increased accessibility of remote ideas. A pilot study from San Francisco State College is described more favourably: 27 participants selected for creative professions received mescaline after preparation and 'priming' to encourage a positive set; all participants performed better on psychometric tests under drug conditions compared with baseline (P < 0.01) and qualitative follow‑up yielded eleven reported 'strategies of enhanced functioning', including reduced inhibition, greater fluency and flexibility of ideas, increased visual imagery, improved problem restructuring, and improved association of dissimilar ideas. At 8‑week follow‑up participants reported either improvement or no change in creativity, with no reported impairments. Sessa notes methodological limitations of these studies, especially the lack of double blinding and placebo control in many cases. Clinical and commercial implications are reported. Early small studies in children with severe autism reportedly showed improved speech, social responsiveness, positive mood and reductions in stereotyped behaviours when psychedelics were used, though these trials were small and were discontinued for socio‑political reasons. Industry anecdotes include architects and computer pioneers who attributed insights to psychedelic experiences; Sessa suggests that if effects were replicable they could have commercial relevance. Safety and variability are also addressed: performance on standard cognitive tests is generally impaired during acute intoxication, and subjective outcomes vary widely depending on 'set and setting' — the user's mindset and the environment. Sessa highlights modern replications of classic work: Roland Griffiths' 2006 recreation of Pahnke's Good Friday experiment administered psilocybin to 36 volunteers with an active control (methylphenidate), producing 61% reporting a 'complete mystical experience' versus 13% in the control group, and 79% of psilocybin subjects reporting increased life satisfaction at 2 months. However, 36% experienced strong to extreme fear during sessions and about 13% had dysphoria that dominated the session. Overall, the empirical material is mixed: some well‑prepared and selected samples report enhancements in aspects of creative cognition or subjective creative experience, while many other controlled studies show null or inconclusive effects. Methodological heterogeneity, small sample sizes, and the importance of set and setting are recurring themes.

Sessa interprets the assembled evidence cautiously. He argues that despite the largely anecdotal and methodologically weak nature of much of the mid‑20th century literature, there are converging reasons to re‑examine whether psychedelics can meaningfully enhance creativity. In particular, he emphasises that studies that prepared and selected participants and paid attention to set and setting (for example the San Francisco State College pilot) are those most likely to report positive effects. The paper therefore positions set and setting not as peripheral confounders but as integral components of a psychedelic intervention. The author situates the findings relative to earlier research by noting that many historical studies reported subjectively profound and sometimes enduring changes, but that objective demonstrations were limited by small samples, lack of blinding, and culturally heterogenous methods. Sessa draws attention to modern replications, such as Griffiths' psilocybin study, which demonstrate both potent subjective effects and the potential for adverse experiences, underscoring safety and the need for careful protocols. Key limitations acknowledged include the poor methodological quality of many historical studies, small and selected samples, lack of systematic measurement in the arts, and the difficulty of obtaining meaningful standard cognitive test data during acute intoxication. Sessa also notes that psychedelics commonly impair performance on standard intelligence and psychomotor tests while potentially enhancing subjective aspects of perception and associative thinking. The variability of outcomes and the possibility of adverse psychological reactions are further uncertainties. For future work, Sessa advocates carefully designed contemporary research that uses rigorous methodology, pays explicit attention to set and setting, selects appropriate participant groups, and employs meaningful outcome measures for creativity. He suggests potential clinical applications (for example in autism) and commercial relevance but urges cautious, scientifically robust exploration rather than speculative or promotional claims.

Sessa concludes that, although psychedelic research must be pursued cautiously given historical controversies, there is a substantial body of anecdotal and preliminary empirical material that was abandoned prematurely and may warrant re‑evaluation. He recommends revisiting the question of psychedelic enhancement of creativity using modern research methods to advance understanding of brain and mind, while acknowledging the need for careful planning to address safety, methodological rigour and the role of set and setting.